A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants

Withdrawn before enrolling · Phase 1

Conditions studied: Renal Insufficiency

In brief

The purpose of the study is to determine whether lanabecestat can be safely prescribed in participants with kidney impairment without a dose adjustment. Participants will be on study for up to 6 weeks; this includes a 2-week screening and a follow-up about 10 days after final drug administration.

Key facts

Study ID

NCT03545087

Run by

Eli Lilly and Company

People needed

0

Starts

2018-06-01

Expected to finish

2019-01-01

Last updated by the study team

2018-06-28

Who can join

Age: 35 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Have a body mass index (BMI) of 19 to 40 kilograms per meter square (kg/m²)

You may not qualify if…

• Have a history of or current significant ophthalmic disease, particularly any eye problem involving the retina
• Have moderate or severe vitiligo or any other clinically significant disorder of skin or hair pigmentation
• Have acute unstable neuropsychiatric disease
• Have active or uncontrolled neurologic disease, or clinically significant head injury

Where it is running

• Orange County Research Center — Tustin, California, United States
• Clinical Pharmacology of Miami — Miami, Florida, United States
• Orlando Clinical Research Ctr. — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.